Protagonist Therapeutics
PTGX
PTGX
77 hedge funds and large institutions have $165M invested in Protagonist Therapeutics in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
31
Reduced
28
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
JPMorgan Chase & Co
New York
|
+$4.41M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.56M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.54M |
| 4 |
RI
RTW Investments
New York
|
+$1.41M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$599K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$3.56M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$1.76M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.06M |
| 4 |
O
OrbiMed
New York
|
-$877K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$734K |
